Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 16:14:1995-2005.
doi: 10.2147/CMAR.S364713. eCollection 2022.

Outcomes of Patients with EGFR- Mutant Advanced NSCLC in a Developing Country in Southeast Asia

Soon Hin How  1   2 , Chong Kin Liam  3 , Muhammad Adil Zainal Abidin  1 , Harissa H Hasbullah  4   5 , Lye Mun Tho  6 , Gwo Fuang Ho  7 , Ibtisam Muhamad Nor  5 , Yong Kek Pang  3 , Kean Fatt Ho  8 , Muthukkumaran Thiagarajan  5 , Roziana Ariffin  9 , Azlina Samsudin  10 , Azza Omar  11 , Sin Nee Tan  2 , Choo Khoon Ong  12 , Sing Yang Soon  13 , Mau Ern Poh  3
Affiliations

Outcomes of Patients with EGFR- Mutant Advanced NSCLC in a Developing Country in Southeast Asia

Soon Hin How et al. Cancer Manag Res. .

Abstract

Background: Although first- and second-generation EGFR TKIs are considered first-line treatment in EGFRm+ NSCLC, most patients develop resistance and progress, commonly, EGFR T790M mutation. The third-generation EGFR-TKI has demonstrated efficacy in patients with progressive disease harboring the T790M mutation and in the first-line setting, bypassing this mode of resistance. The primary objectives of this study are to describe the proportion of EGFRm+ NSCLC patients treated with first-, second- and third-generation EGFR TKIs, and cytotoxic chemotherapy in the first-line setting, and the time on treatment for each category. Secondary objectives are to determine the dropout rate, the rates for T790M mutation testing at disease progression and the type of subsequent treatment.

Methods: This multicenter retrospective study utilized data from the Malaysian Lung Cancer Registry that actively registers all lung cancer patients ≥18 years, with primary lung cancer confirmed histologically or cytologically. All patients diagnosed with advanced stages (ie stages IIIB, IIIC and IV) EGFRm+ NSCLC from 1st of January 2015 to 31st December 2019 were included.

Results: Of 406 patients with EGFRm+ NCSLC, 351 were treated. Types of first-line treatment were as follows: EGFR-TKIs (first generation - 54.1%, second generation - 25.6% and third-generation - 12.5%) and chemotherapy (7.7%). The median time of treatment for each generation of EGFR-TKI was 12 months, 12 months and 24 months, and 2 months for chemotherapy. The dropout rate was 28.7% (n = 101). Nearly half (49.4%) of patients who were on first- or second-generation EGFR-TKI had further genetic testing via liquid or tissue biopsies upon disease progression. About 24.9% of those who developed disease progression after first- or second-generation EGFR TKI were started on a third-generation EGFR TKI.

Conclusion: In the real-world, the management of EGFRm+ advanced NSCLC patients in an Asian cost-restrictive setting may adversely affect the choice of first-line therapy, time on each line of treatment and subsequently the overall survival of patients.

Keywords: lung cancer; overall survival; time on treatment; tyrosine kinase inhibitors.

PubMed Disclaimer

Conflict of interest statement

CKL has received research grants and honoraria from Astra Zeneca, Boehringer Ingelheim, MSD, Novartis, Pfizer, Roche and Zuellig Pharma. HHH has received research grants and honoraria from Astra Zeneca, EISAI, MSD, Novartis and Tessa Therapeutics; AB science, AdipoLab, Arcus Bioscience. GFH has received research grants and honoraria from AB Science, Arcus Biosciences, Ipsen, Astellas, Astra Zeneca, Eli Lily, Boehringer Ingelheim, BMS, MSD, MIRARI Therapeutics, Novartis, Pfizer, Regeneron, Roche and Tessa Therapeutics, respectively. LMT has received honoraria from Astra Zeneca, Boehringer Ingelheim, Roche, MSD and Pfizer. The other authors have no conflicts of interest to declare in this work.

Figures

Figure 1
Figure 1
Patient flow.
Figure 2
Figure 2
Time on treatment (TOT) according to first-line treatment excluding patients lost to follow-up (N=279).
Figure 3
Figure 3
Overall survival (OS) according to first-line treatment excluding patients lost to follow-up (N=250).
Figure 4
Figure 4
Overall survival (OS) after first-line first- and second-generation EGFR TKIs with and without third-generation EGFR-TKI.
See this image and copyright information in PMC

References

    1. Ministry of Health, Malaysia. Malaysia National Cancer Registry report 2012–2016; 2019.
    1. Ministry of Health, Malaysia. Malaysian study on cancer survival (MySCan); 2018.
    1. Kan CS, Chan KM. A review of lung cancer research in Malaysia. Med J Malaysia. 2016;71(Suppl 1):70–78. - PubMed
    1. Shi Yeen TN, Pathmanathan R, Shiran MS, Ahmad Zaid FA, Cheah YK. Detection of epidermal growth factor receptor mutations in formalin fixed paraffin embedded biopsies in Malaysian non-small cell lung cancer patients. J Biomed Sci. 2013;20(1):22. - PMC - PubMed
    1. Werutsky G, Debiasi M, Sampaio FH, et al. P1.08: updated analysis of global epidemiology of EGFR Mutation in advanced non-small cell lung cancer: track: prevention, early detection, epidemiology and tobacco control. J Thorac Oncol. 2016;11(10):S184–S185. doi:10.1016/j.jtho.2016.08.030 - DOI